AlphaGen
Access AlphaGen
Company Narratives

Siddiqsons Tin Plate FY2026 Results: Turnaround Achieved, but Fragile

STPL returned to a slim FY2026 profit as sales, gross margin and finance costs improved, but the June quarter and liquidity remain weak.

Oct 26, 2026STPLShare price, results & dividends

Verdict: Siddiqsons Tin Plate Limited (STPL) completed a real but fragile turnaround in its audited consolidated results for the year ended June 30, 2026. Revenue rose 40.1%, gross profit increased 50.9%, finance cost fell 37.3%, and the company moved from a Rs255.1 million loss to a Rs3.2 million profit. The catch is material: the June quarter slipped back into loss, the full-year net margin was only 0.1%, and current liabilities still exceeded current assets by about Rs2.17 billion.

Results at a glance

The comparison below is FY2026 against FY2025, in Pakistani rupees. Percentages are calculated from the reported figures.

  • Net sales: Rs2,834.1 million, up 40.1% from Rs2,023.0 million.
  • Gross profit: Rs334.6 million, up 50.9% from Rs221.8 million; gross margin improved to 11.81% from 10.96%.
  • Operating profit: Rs223.9 million versus about Rs95 million; operating margin improved to 7.90% from 4.70%.
  • Finance cost: Rs240.0 million, down 37.3% from about Rs383 million.
  • Profit before tax: Rs38.6 million versus a Rs230.0 million loss.
  • Profit after tax: Rs3.2 million, or Rs0.01 per share, versus a Rs255.1 million loss and loss per share of Rs1.11.
  • Dividend: none declared for the year.

These are consolidated annual figures. The official PSX announcement sheet identifies STPL’s result as consolidated, and the annual report contains the audited company and group accounts. The company’s own financial-statements page had not yet added the FY2026 annual report when checked, so the PSX filing is the controlling current source.

The full-year recovery was operating-led

The headline improvement began above the financing line. Sales added Rs811.1 million year on year, while gross profit increased by Rs112.9 million. Because gross profit grew faster than revenue, gross margin expanded by roughly 84 basis points. That combination matters: STPL did not return to profit solely because of lower interest expense.

Management attributes the sales increase to higher production volumes, improved customer relationships and the return of customers who had paused purchases in earlier years. It also says better raw-material availability allowed the plant to operate closer to an efficient level. Those are company-reported explanations. The filing does not provide a clean price-versus-volume-versus-mix bridge, so the exact contribution from selling prices or product mix cannot be verified and is not assumed here.

The operating arithmetic is nevertheless clear. Cost of sales rose 38.8%, slower than the 40.1% sales increase. That generated the margin gain and helped operating profit rise to Rs223.9 million. The recovery follows two unusually weak years: STPL recorded a Rs55.5 million gross loss in FY2024 and then restored an 11.0% gross margin in FY2025. FY2026 extends that recovery, but it does not yet demonstrate a structurally high-margin business.

Lower finance cost completed the turnaround

Finance cost declined by about Rs143 million to Rs240.0 million. Management links the reduction to declining KIBOR and lower borrowing costs. This was decisive: operating profit exceeded finance cost by only a modest amount once other items were included, leaving profit before tax at Rs38.6 million.

Other income was approximately Rs64.1 million, below the roughly Rs71 million recorded a year earlier, so the turnaround was not driven by a larger non-operating income contribution. Other charges also remained comparatively small at about Rs9.4 million after the large exceptional expense burden of FY2024 had already fallen away in FY2025.

Tax expense of Rs35.4 million absorbed almost 92% of pre-tax profit. That reduced the final profit to Rs3.2 million and the net margin to just 0.11%. The company has therefore crossed back into profit, but with almost no earnings cushion against a weaker gross margin, higher finance cost or another exceptional charge.

The fourth quarter weakened again

The annual result looks stronger than the exit rate. Subtracting the nine-month figures from the audited full-year totals gives a derived June quarter; this is a calculation, not a separately reported quarterly statement.

Derived fourth-quarter sales were about Rs676.1 million, 36.3% above the corresponding quarter a year earlier. Gross profit was about Rs34.6 million, reversing the prior-year fourth-quarter gross loss of roughly Rs21 million. However, the quarter’s gross margin was only 5.1%, far below the 13.7%–14.1% range achieved in the first three quarters of FY2026.

That compression pushed the derived quarter to an operating loss of about Rs1.1 million, a pre-tax loss of Rs23.4 million and a net loss of Rs32.8 million. The loss was much smaller than the approximately Rs81 million loss in the June 2025 quarter, but it shows that STPL’s recovery was not yet stable at year-end. The filing does not disclose enough price, mix, raw-material or utilization detail to assign the margin drop to one cause.

What improved

  • The most important improvement is that gross profitability survived a 40% expansion in sales. In FY2024, fixed-cost absorption and market disruption contributed to a gross loss. By FY2026, STPL had rebuilt positive gross profit and improved the annual margin for a second consecutive year.
  • Interest pressure eased. A 37.3% reduction in finance cost converted much more of the operating recovery into pre-tax earnings. The improvement is economically meaningful even though absolute finance cost remains heavy relative to profit.
  • The working-capital deficit narrowed. Current assets rose to Rs1.14 billion while current liabilities fell to Rs3.31 billion, reducing the deficit to approximately Rs2.17 billion from about Rs2.38 billion a year earlier.
  • The company retained customers and recovered business, according to management, despite the structural competitive issues it continues to flag in the domestic market.

What weakened or needs attention

  • Quarter-end profitability deteriorated. The derived June quarter erased some of the momentum established earlier in the year, and its 5.1% gross margin was less than half the full-year rate.
  • Liquidity remains tight. Current liabilities were about 2.9 times current assets. Cash and bank balances fell to only Rs5.3 million from about Rs34 million, leaving very little liquid buffer.
  • Working capital absorbed more resources. Inventory rose 44% to Rs291.5 million and trade receivables increased 79% to Rs346.3 million. Together they increased by roughly Rs242 million, even as year-end cash declined.
  • Borrowings did not fall with finance cost. Total debt increased about 5.8% to Rs1.11 billion, and almost all of it remained short term. Lower rates helped the income statement, but the financing structure is still vulnerable to refinancing conditions and rate reversals.
  • Retained losses remained approximately Rs1.38 billion, while total equity was about Rs910.6 million. The small FY2026 profit does not repair the accumulated deficit in any meaningful way.

Cash flow and balance-sheet interpretation

The balance-sheet recovery is less convincing than the income-statement recovery. Total assets declined about 5.1% to Rs4.22 billion, while equity was broadly flat. The reduction in current liabilities is positive, but it was not accompanied by lower debt or stronger cash.

The annual filing provides full-year cash-flow information but not a separately reported June-quarter cash-flow statement. Accordingly, no claim is made about June-quarter cash conversion. The year-end movements in inventory, receivables and cash are sufficient to show that accounting profit did not translate into an obvious strengthening of near-cash liquidity.

Industry constraints remain company-specific risks

Management continues to identify two market distortions: the use of Galvalume sheets in food packaging and tax-exempt products from FATA/PATA entering tariff areas. These are management’s stated industry concerns, not independently adjudicated conclusions in this analysis. The company says no concrete corrective measures had been implemented by the reporting date.

Management’s outlook is mixed. It expects macroeconomic stability and lower inflation to support demand, while continuing to focus on operating efficiency, cost control, customer retention and markets beyond the domestic base. The central analytical question is whether higher utilization can persist without sacrificing the gross margin, especially after the weaker June quarter.

AlphaGen model scores

The following are AlphaGen model outputs, not company-reported figures and not investment recommendations. Only the four approved operating and relative-performance scores are shown.

  • Alpha QoQ Score: 39.77
  • TTM Performance Score: 94.07
  • 3Y Business Perf Score: 58.72
  • Sector Leadership Score: 50.31

The contrast between the strong TTM score and weaker quarter score fits the financial pattern: the full year improved sharply from a low base, while the final quarter lost momentum.

What to monitor next

  • Gross margin in the September 2026 quarter. A recovery toward the FY2026 average would support the case that the June compression was temporary; another quarter near 5% would weaken it.
  • Volume retention and utilization. Management has linked the sales recovery to higher production and returning customers, so the next report should show whether those gains persisted.
  • Short-term borrowing and finance cost. The benefit from lower rates is clear, but the debt balance increased and remains concentrated in short-term facilities.
  • Receivable collection and inventory discipline. With cash at Rs5.3 million, the release of working capital is more important than another small accounting profit.
  • Progress on structural market issues and export/customer diversification. Until there is evidence of a durable response, these should remain risks rather than assumed upside.

Sources

This analysis explains reported results and disclosed risks; it is not a buy or sell recommendation.

Explore more research

All articles